As shown in Figure 3B, the triptolide treatment significantly augmented the expression levels of LC3B and Beclin-1 and dramatically reduced the expression level of p62 in a dose- and time-dependent manner in the glioma cells. This evidence concerns the gene MAP1LC3B and central nervous system cancer.